Skip to main content
Premium Trial:

Request an Annual Quote

Science's One-Two Punch

Writing in the Los Angeles Times, Meryl Comer and Chris Mooney say those worried about mending the economy should consider investing in scientific research. "In a country where 65 percent of the citizens can't name a living scientist and another 18 percent try but get it wrong," Comer and Mooney say that it's a mistake not to ramp up funding for science. In discussing the economic reverberations of research achievements, the authors reflect on how Nobel laureate Robert Solow "documented that advances in technology and knowledge drove US economic growth in the first half of the 20th century." Beyond creating jobs alone, scientific research can also "save society a fortune" in shared healthcare costs, the pair writes. At a time when Republicans seek to cut federal science budgets to pre-stimulus levels, Comer and Mooney say it's time for Americans "to honor our scientists. … We need to recognize that the cost of basic science, and the time it takes, require a sustained government commitment."

HT: Mike the Mad Biologist

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.